Rxivist logo

Immunotherapy is becoming a mainstay in the treatment of NSCLC. While tumor mutational burden (TMB) has been shown to correlate with response to immunotherapy, little is known about the relation of the baseline immune response with the tumor genotype. Here, we profiled 35 early stage NSCLC lesions using multiscale single cell sequencing. Unsupervised clustering identified in a subset of patients a key cellular module consisting of PDCD1+ CXCL13 + activated T cells, IgG+ plasma cells, and SPP1 + macrophages, referred to as the lung cancer activation module (LCAMhi). Transcriptional data from two NSCLC cohorts confirmed a subset of patients with LCAMhi enrichment, which was independent of overall immune cell content. The LCAMhi module strongly correlated with TMB, expression of cancer testis antigens, and with TP53 mutations in smokers and non-smokers. These data establish LCAM as a key mode of immune cell activation associated with high tumor antigen load and driver mutations. ### Competing Interest Statement Research support for this work was provided by Regeneron and Takeda. The authors declare no other competing financial interests.

Download data

  • Downloaded 2,575 times
  • Download rankings, all-time:
    • Site-wide: 5,868
    • In immunology: 194
  • Year to date:
    • Site-wide: 2,169
  • Since beginning of last month:
    • Site-wide: 1,338

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide